Kiromic Biopharma, Inc.: Nasdaq/NYSE listing notice — Kiromic BioPharma receives Nasdaq deficiency notice for audit committee non-compliance

Kiromic Biopharma, Inc.

Frank Tirelli resigned as director effective Nov 16, 2022, leaving audit committee with fewer than 3 independent members.
Nasdaq requires audit committee of at least 3 independent directors per Listing Rule 5605(c)(2)(A).
Cure period until earlier of next annual shareholders' meeting or Nov 16, 2023; stock continues trading on Nasdaq.
Board's Nominating and Corporate Governance Committee is seeking qualified candidates to fill vacancy.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Kiromic Biopharma, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: audit committee
Rules: 5605(c)(2)(A)

Exact text from the filing

December 6, 2022, Kiromic BioPharma, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the audit committee requirements as set forth in Nasdaq Listing Rule 5605 for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5605(c)(2)(A) requires companies listed on The Nasdaq Capital Market to maintain an audit committee consisting of at least three independent directorsmembers, with one of which being classified as a financial expert. As

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-22-018543

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.